Background: This population-based cohort study was to compare the risks of incident cancer in osteoporosis patients who used bisphosphonates, calcitonin or selective estrogen receptor modulators (SERMs). Methods: We identified 9995 patients who were diagnosed with osteoporosis and prescribed osteoporosis drugs (bisphosphonate (n = 4675), calcitonin (n = 3993) and SERMs (n = 1327)) between 1 January 2000 and 31 December 2006 in Taiwan's National Health Insurance Research Database. Date of first prescription of osteoporosis drugs was assigned as the index date. The outcome measurement was incident cancer, defined by a first-ever inpatient visit with a primary diagnosis of cancer. All patients were followed until the occurrence of cancer. For those who did not develop cancer, we censored them at 1 year after their last prescription of osteoporosis drugs. Cox proportional hazard models were used to examine the association between risk of cancer and use of calcitonin, bisphosphonates or SERMs. Results: The incidence rate of cancer was 68.8, 34.0 and 29.6 per 1000 person years in the calcitonin, SERMs and bisphosphonate cohorts, respectively. Compared with bisphosphonate users, calcitonin users were associated with an increased risk of cancer (adjusted hazard ratio (HR) 2.11, 95% confidence interval (CI) 2.01-2.21, P < 0.001). SERM users were associated with an increased risk of cancer (adjusted HR 1.20, 95% CI 1.13-1.28, P < 0.001). Conclusion: Our findings suggest that calcitonin is associated with an increased risk of cancer than bisphosphonate, supporting the recent warning issued by the European Medicines Agency and US Food and Drug Administration. SERMs is found to be associated with an increased risk of cancer than bisphosphonate.
Introduction
Osteoporosis is a skeletal disorder characterized by affected bone strength due to low bone density and disruption of bone architecture, which leads to an increased risk of fracture. Therefore, it is an important cause of morbidity and mortality particularly among the elderly (1, 2) . According to a lifetime model of osteoporosis impact, 20% of patients with osteoporotic hip fracture do not survive for more than a year from diagnosis, and over 50% never completely regain their pre-fracture status (3) .
A number of pharmacologic agents, including bisphosphonates, selective estrogen receptor modulators (SERMs) and calcitonin, are approved for the treatment of osteoporosis with the optimal goal to reduce bone turnover and then osteoporotic fractures (4) (5) (6) (7) . Calcitonin is a hormone that helps regulate calcium levels in human body and is involved in the process of bone building. Therefore, it is one of the pharmacological agents used for patients with osteoporosis. In an early clinical trial of 1255 postmenopausal women with established osteoporosis, the use of salmon calcitonin nasal spray significantly decreased 5-year vertebral fracture risk by 33% relative to placebo (8) .
Nevertheless, safety concerns regarding the use of calcitonin have been raised recently. On 19 July 2012, the European Medicines Agency (EMA) suggested that there was evidence of a small increased risk of cancer with long-term use of these medicines after completing a review of the benefits and risks of calcitonin-containing medicines. A subsequent warning issued by the US Food and Drug Administration (FDA) advisory committees further suggest that use of a nasal spray formulation of calcitonin for treatment of postmenopausal osteoporosis is associated with an increased risk of cancer (9) .
Despite safety signals reported from the Western countries, there is no population-based epidemiological study regarding the association between calcitonin and risk of cancer. Furthermore, the association between other osteoporosis drugs and the risk of cancer is questioned. For example, alendronate was reported to be associated with esophageal cancer in previous studies (10, 11 
Methods

Data source
This is a population-based cohort study using NHIRD. The NHIRD are a nationwide database comprising anonymous eligibility and enrollment information, as well as claims for visits, procedures, and prescription medications of more than 99% of the entire population (23 million) in Taiwan. Individual patients are recorded as entering the NHIRD when they are covered by Taiwan's mandatory National Health Insurance (NHI) program since 1996 and leave because of death. For each visit, the NHIRD has recorded dates of visits (outpatient visits, admissions and discharges) and up to five diagnoses coded by physicians according to the International Classification of Disease, ninth Edition (ICD-9 CM codes). The completeness and the accuracy of the NHIRD are ensured by the Department of Health and the Bureau of NHI of Taiwan. The database has been described in detail elsewhere (12) and has been the source for numerous epidemiological studies published in peerreviewed journals (13) (14) (15) .
Three subsets of the NHIRD, the Longitudinal Health Insurance Database 2000, 2005 and 2010, which contain claims data of 1 million beneficiaries randomly sampled from the Registry of Beneficiaries in 2000, 2005 and 2010, were used in this study. A total of 3 million individuals, which accounted for 15% of the total population in Taiwan, were thus served as our original cohort. The age and gender distributions of the LHID are not significantly different from those of the general population. The longitudinal nature of LHID permits one to identify a cohort based upon diagnoses, health services, and drug utilization, track medical history, establish a prescription drug profile and determine the endpoint of drug treatment.
Ethical statement
Because the identification numbers of all subjects in the NHRID were encrypted to protect the privacy of the individuals, this study was exempted from full review by the Institution Review Board of the National Taiwan University Hospital and informed consents were waived (NTUH-REC-201 403 069 W). osteoporosis drugs from one category to another were excluded to ensure mutually exclusive drug exposure groups in our study.
Study population
Patients who had any record of inpatient visit with a primary diagnosis of any cancer (ICD-9 CM codes: 140.xx-239.xx) 1 year prior the index date were excluded.
Statistical analyses
The primary endpoint was outpatient or inpatient visits with a diagnosis for malignancy (ICD-9-CM code: 140.xx-239.xx) after the index date. Only patients who had more than one visits with cancer diagnosis were defined as our cancer cases to confirm the diagnosis of cancer. All case patients were followed until the occurrence of cancer. For those who did not develop cancer during the follow-up period, we censored them at 1 year after their last prescription date of osteoporosis medications. Cox proportional hazards regression models were used to assess the association between use of osteoporosis medications (bisphosphonate, calcitonin or SERMs) and cancer risks. All models adjusted for age, gender, year of initiating antiosteoporosis agents, and concomitant diseases including diabetes mellitus, hypertension, heart failure, stroke, transient ischemic attack, osteoarthritis, chronic obstructive pulmonary disease (COPD) and depression. The associations are presented as hazard ratios (HRs) with 95% confidence intervals (CIs). HRs of our main focus (exposure to osteoporosis drugs) by each potential confounding factor were also examined. The two-sided P values less than 0.05 were considered statistically significant. All analyses were performed with SAS, version 9.1 (SAS Institute Inc, Cary, NC).
Results
We identified 4675, 3993 and 1327 osteoporosis patients who received bisphosphonate, calcitonin and SERMs, respectively (Fig. 1) . Women accounted for a large proportion of osteoporosis drugs users (bisphosphonate, 84.15%; calcitonin, 78.69% and SERMs, 98.72%) ( Table 1) . Compared with bisphosphonate cohort, a higher proportion of patients in calcitonin and SERMs cohort were aged 85 years old (bisphosphonate, 7.91%; calcitonin, 11.08% and SERMs, 9.27%). The SERMs cohort was less likely to have a concomitant diagnosis of stroke. The calcitonin cohort was less likely to have a concomitant diagnosis of osteoarthritis and depression but was more likely to have a concomitant diagnosis of chronic obstructive pulmonary disease (COPD) ( Table 1) . During follow-up, 458 (9.8%), 563 (14.1%) and 121 (9.1%) cases of incident cancer were found in the bisphosphonate, calcitonin and SERMs cohorts, respectively. The incidence rate of cancer was 68.8 per 1000 person years in the calcitonin cohort compared with 34.0 per 1000 person years in the SERMs cohort and 29.6 per person years in the bisphosphonate cohort. The incidence rates of cancer were higher in men than women among all three cohorts (bisphosphonate cohort: 53.2 vs. 26.2 per 1000 person years, calcitonin cohort: 95.8 vs. 62.1 per 1000 person years, SERMs cohort: 147.1 vs. 32.9 per 1000 person years). The incidence of cancer increased with age in the bisphosphonate cohort but not in other two cohorts (Table 2) . Table 3 lists the types of cancer observed among bisphosphonate, calcitonin and SERMs cohorts. Cancers of lung, colon and liver were the most common cancer sites diagnosed among both calcitonin and bisphosphonate cohorts. Among SERMs cohort, cancer of breast, liver and lung were the most common cancer sites diagnosed.
Compared with bisphosphonate users, calcitonin users were associated with an increased risk of cancer (adjusted HR 2.11, 95% CI 2.01-2.21, P < 0.001). SERMs users were associated with an increased risk of cancer (adjusted HR 1.20, 95% CI 1.13-1.28, P < 0.001). (Table 4) .
Similar results were found when examining the HRs of exposure to osteoporosis drugs by each potential confounding factor. Compared with bisphosphonate users, calcitonin users were associated with an increased risk of cancer (Fig. 2) . 
Discussion
To our knowledge, this is the first head-to-head comparative study to examine potential cancer risks among different osteoporosis drug users. Our population-based cohort study shows that the calcitonin and SERMs users are associated with increased cancer risks as compared with bisphosphonate users.
Our findings have major implications for clinical practice, particularly in light of the increasing prevalence of osteoporosis and the potential life-long needs for osteoporosis medications among these patients. Bisphosphonate was found to be associated with the lowest cancer risk among three osteoporosis drugs in this study. Our findings, combined with evidence from existing studies (16) (17) (18) showing its benefits in the secondary prevention of hip fractures, suggest that bisphosphonate may remain the first line drug of choice for osteoporosis management. In addition, our data add to the evidence that use of calcitonin is associated with increased risk of cancer. As available data on the safety profile of calcitonin is very limited, our data are of great value in promoting public health.
To our knowledge, this is the first epidemiological study providing empirical data of head-to-head comparisons of cancer risks among different osteoporosis medications. We found that use of calcitonin is associated with 2-folds increase in the risk of cancer compared with use of bisphosphonates. The cancer risks associated with calcitonin found in our study (adjusted HR 2.11, 95% CI 2.01-2.21, P < 0.001) was consistent with data from clinical trials released from the US FDA (calcitonin vs. placebo odds ratio (OR) 1.6; 95% CI, 1.1-2.3) (9). In addition, our study provides further evidence by using bisphosphonate users as the reference group instead of placebo.
SERMs was found to be associated with an increased risk of cancer in this study.
The mechanism behind this link is unknown. In cell line and animal studies, bisphosphonate may reduce angiogenesis and induce tumor apoptosis (19, 20) , which implies a potential benefit in suppressing tumor recurrence in selected patients. However, it would be inappropriate to conclude that alendronate had a more pronounced protective cancer effect than SERMs. In fact, one case report (21) and one recent case-control study (10) which conducted using UK's General Practice Research Database (GPRD) have suggested a potential risk of esophageal cancer associated with long-term use of bisphosphonate. Interestingly, another study using UK's GPRD suggested that use of oral bisphosphonates was not associated with esophageal cancer (22) . Using Taiwan's NHIRD as data source, our previous nested case-control study also found that alendronate use was not significantly associated with incident esophageal cancer (13) . Based on this study, along with existing studies, benefits of bisphosphonate appeared to outweigh its risks among all available osteoporosis medications.
The strength of this study is the population-based design within a universal health care system with complete outpatient and inpatient visit information and prescriptions. The nationwide database also allowed us to identify a great number of osteoporosis patients treated with bisphosphonate, calcitonin or SERMs. Furthermore, the cohort study design is better suited to evaluate the association between drug exposure and long-term risks such as cancer. Secondly, restricting analyses to new users of osteoporosis drugs and their incident cancers allowed us to adjust potential cross-over effects.
This study has several limitations, all generally related to the use of claims data. Firstly, other factors that may contribute to development of cancer, such as family history, diet and exercise, could not be obtained from the databases.
A second limitation of our study is we identified our cancer cases based on the inpatient or outpatient diagnosis of cancer but not histopathology report, which may overestimate the cancer cases. Nevertheless, as all NHI beneficiaries diagnosed with cancer is required to have a confirmed cancer diagnosis from the hospital to be eligible for a Certificate of Catastrophic Illness to be exempted from all copayments, the overestimation could be small in our study. Thirdly, we examined cancer risks of calcitonin or SERM compared with bisphosphonates. This design aimed to do head-to-head comparisons to reflect treatment choices in 'real-world' settings but could not. Finally, we could not confirm whether or not the patients had adhered to the directions for taking their prescriptions of osteoporosis medications.
Conclusion
The findings of this large population-based study show that use of calcitonin is associated with an~58% increase in the risk of cancer compared with use of bisphosphonates. In addition, the present study suggest that use of SERMs is associated with an~27% increase in the risk of cancer compared with use of bisphosphonates.
